New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
10:31 EDTBIOS, NVSNovartis accused of paying kickbacks to bolster Exjade sales, Bloomberg says
Novartis (NVS) was accused by a group of states and the U.S. of paying BioScrip (BIOS), a specialty pharmacy, kickbacks to bolster sales of Exjade, says Bloomberg. Exjade is an iron-control drug that can cause kidney and liver failure, added Bloomberg. Reference Link
News For NVS;BIOS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
09:50 EDTNVSMylan launches generic Exforge tablets in U.S.
Subscribe for More Information
March 30, 2015
17:46 EDTNVSNovartis announces FDA approval for Jadenu
Subscribe for More Information
05:18 EDTNVSNovartis enters multiyear aliance with Aduro Biotech
Subscribe for More Information
March 26, 2015
11:13 EDTNVSBofA/Merrill European pharma analyst holds an analyst/industry conference call
Subscribe for More Information
10:18 EDTNVSHigh option volume stocks
High option volume stocks: BTX ALL FIVE SGYP SWFT RHT IDCC NVS WGO XBI
March 24, 2015
11:05 EDTNVSNovartis granted orphan status for medulloblastoma treatment
Subscribe for More Information
March 23, 2015
09:47 EDTBIOSBioScrip management to meet with Barrington
Meeting to be held in Minneapolis on March 30 hosted by Barrington.
09:45 EDTNVSUBS to hold a field trip
Subscribe for More Information
09:03 EDTNVSLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 20, 2015
12:33 EDTNVSNovartis says CLEAR Phase IIb study met primary endpoint
Novartis announced results from the CLEAR study demonstrating that Cosentyx is significantly superior to Stelara, a widely used biologic, in achieving clear or almost clear skin for psoriasis patients. The detailed findings were presented in a late-breaking research session at the 73rd Annual Meeting of the American Academy of Dermatology in San Francisco, USA. Cosentyx -- at a dose of 300 mg -- is the first and only interleukin-17A inhibitor approved to treat adult patients with moderate-to-severe plaque psoriasis. In this Phase IIIb study, Cosentyx met the primary endpoint of showing superiority to Stelara as assessed by the Psoriasis Area Severity Index 90 response, known as clear to almost clear skin at Week 16. PASI 90 is considered an important measure of treatment success by the European Medicines Agency and an optimal treatment goal for patients. In addition, completely clear skin at Week 16 was achieved by significantly more patients treated with Cosentyx than those receiving Stelara. In addition, Cosentyx demonstrated rapid onset of action and greater efficacy at all time points in the study up to Week 16, with 50% of Cosentyx patients achieving PASI 75 as early as Week 4 compared to Stelara. The CLEAR study follows the pivotal Phase III FIXTURE study, which showed Cosentyx was superior to Enbrel.
10:25 EDTBIOSBioScrip management to meet with SunTrust
Meetings to be held in New York on March 24 and in Boston on March 25 hosted by SunTrust.
07:41 EDTNVSAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
17:30 EDTBIOSColiseum Capital reports 18.6% stake in BioScrip
15:55 EDTNVSAmgen injunction bid for Neupogen biosimilar denied, Reuters reports
Subscribe for More Information
15:13 EDTNVSAmgen denied preliminary injunction for biologics against Novartis, Reuters says

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use